Paclitaxel: a review of adverse toxicities and novel delivery strategies

Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemothera...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on drug safety Vol. 6; no. 5; p. 609
Main Authors Marupudi, Neena I, Han, James E, Li, Khan W, Renard, Violette M, Tyler, Betty M, Brem, Henry
Format Journal Article
LanguageEnglish
Published England 01.09.2007
Subjects
Animals
Drug Delivery Systems - methods
Drug Delivery Systems - trends
Humans
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel - chemistry
Online AccessGet more information

Cover

More Information
Summary:Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.
ISSN:1744-764X
DOI:10.1517/14740338.6.5.609